European Patent Office

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Retrieved on: 
Monday, March 11, 2024
Therapy, European Patent Office, UBC, University, Patent, University of British Columbia, IP Australia, PMN, Japan Patent Office, PROMIS, Patient, Neuroscience

The United States Patent and Trademark Office also recently granted US Patent 11,905,317 directed to immunogenic compositions of matter that are being developed for treating AD.

Key Points: 
  • The United States Patent and Trademark Office also recently granted US Patent 11,905,317 directed to immunogenic compositions of matter that are being developed for treating AD.
  • Protection for the immunogenic compositions of matter has also been obtained in Japan, Korea, India and Australia.
  • Further, patent applications were also recently allowed in the U.S. and Japan for two other Aβ targets.
  • “We are building a fortress of intellectual property protection around our novel approach to targeting toxic misfolded proteins to treat neurodegenerative diseases and these newly allowed patents validate that innovation in important geographies around the world,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent

Retrieved on: 
Thursday, November 16, 2023
European Patent Office, Therapy, Ageing, Windtree Therapeutics, Heart, Patient, Heart failure, European Patent Convention, Diagnosis, Patent, Family, Hospital, PURE, Pharmaceutical industry

3805243, providing composition of matter patent coverage for the pure SERCA2a Activator class of drug candidates.

Key Points: 
  • 3805243, providing composition of matter patent coverage for the pure SERCA2a Activator class of drug candidates.
  • The pure SERCA2a Activators are one of two families of preclinical drug candidates that act on SERCA2a in the Company’s pipeline.
  • The new European patent, titled: “ANDROSTANE DERIVATIVES WITH ACTIVITY AS PURE OR PREDOMINANTLY PURE STIMULATORS OF SERCA2A FOR THE TREATMENT OF Heart Failure,” provides patent protection until October 9, 2039 for the family of compounds with the pure SERCA2a mechanism of action.
  • Windtree believes activation of SERCA2a represents a potentially important advancement in heart failure treatment for patients,” said Craig Fraser, CEO of Windtree Therapeutics.

Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine

Retrieved on: 
Friday, November 10, 2023
European Patent Office, Therapy, Betahistine, Patient, European, Intellectual property, European Patent Convention, EPO, RNA, Patent, Pharmaceutical industry

November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has received an “Intention to Grant” notice from the European Patent Office (EPO) for its patent application titled “Intranasal Composition Comprising Betahistine” (designated as European Patent 3698791).

Key Points: 
  • November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has received an “Intention to Grant” notice from the European Patent Office (EPO) for its patent application titled “Intranasal Composition Comprising Betahistine” (designated as European Patent 3698791).
  • The application is a continuation of the previously granted European Patent 3474850 and upon issuance, is expected to remain valid until February 2038.
  • Combined, these two patents will provide key intellectual property protection for the Company's intranasal betahistine program (AM-125) in Europe.
  • “We are very pleased with the continued expansion of our patent portfolio covering the intranasal betahistine program,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman and CEO.

The European Patent Office (EPO) Rules in Favor of Mara and AO3 on Validity of DSM Patent EP3530740

Retrieved on: 
Monday, November 27, 2023
Vitamins, Supplements, Manufacturing, Other Manufacturing, Health, Fitness & Nutrition, European Patent Convention, EPO, European Patent Office, DSM, AO3, DHA, Patent, Dietary supplement

Mara Renewables Corporation, and its manufacturing partner Algal Omega-3 (AO3) announced today that the European Patent Office (EPO), Opposition Division, has ruled in favor of Mara regarding the validity of DSM’s patent EP3530740, titled “Thraustochytrids, fatty acid compositions, and methods of making and uses thereof.”

Key Points: 
  • Mara Renewables Corporation, and its manufacturing partner Algal Omega-3 (AO3) announced today that the European Patent Office (EPO), Opposition Division, has ruled in favor of Mara regarding the validity of DSM’s patent EP3530740, titled “Thraustochytrids, fatty acid compositions, and methods of making and uses thereof.”
    The EPO panel decided the DSM patent as granted is not valid and that its scope must be significantly narrowed.
  • As a result, the microbial oils claimed by the patent are now limited to those containing at least 60% DHA in the triglyceride fraction, up from a previous limit of at least 50% DHA.
  • “We are pleased with the decision of the EPO opposition division.
  • We will also look to enforce our own intellectual property in a responsible manner.

Cybin Reports Second Quarter Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Mental Health, Other Science, Research, Science, Clinical Trials, Food and Drug Administration, Indian stock exchange, Depression, Safety, NYSE, Tryptamine, Acquisition, DMT, Food, DSM-IV codes, Completeness, European Patent Office, Warrant, Initiate, Acceleration, Exercise, Model Business Corporation Act, NEO, Data, Patient, European Patent Convention, Anxiety, MADRS, Phase, Mental health, Patent, Inc., Offering, MDD, Pharmaceutical industry, Security (finance), Medical imaging, Unit

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended September 30, 2023, and recent business highlights.

Key Points: 
  • Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended September 30, 2023, and recent business highlights.
  • “We have made enormous progress during the past quarter, with ample momentum to carry us through year-end and into 2024.
  • Announced unprecedented positive Phase 2 interim data for CYB003, the Company’s proprietary deuterated psilocybin analog, in major depressive disorder (“MDD”).
  • Cash-based operating expenses totaled C$12.5 million for the quarter ended September 30, 2023, compared to C$11.3 million, in the prior year quarter, of which C$2.1 and C$2.0 million were one-time costs, respectively.

Darling Ingredients' health brand Rousselot receives U.S. Patent for gelatin technology that improves soft gel capsule stability and efficacy

Retrieved on: 
Monday, December 4, 2023
NYSE, European Patent Office, DAR, Cross-linking, European Patent Convention, EPO, Nutrient, Patent, Gelatin, 3D printing, Rousselot

11795489B2 to its health brand Rousselot, securing Rousselot's intellectual property rights for StabiCaps™, a specialized gelatin that improves the formulation and stability of soft gel capsules to enhance the release of active ingredients, including medications.

Key Points: 
  • 11795489B2 to its health brand Rousselot, securing Rousselot's intellectual property rights for StabiCaps™, a specialized gelatin that improves the formulation and stability of soft gel capsules to enhance the release of active ingredients, including medications.
  • StabiCaps addresses crosslinking, a common challenge in the dissolution of soft gel capsules that results in slower or incomplete release of nutrients or pharmaceutical ingredients contained within the capsule.
  • "StabiCaps is an essential innovation for soft gel capsule manufacturers because gelatin is a primary ingredient," said Pierre-Albert Thomas, Rousselot Functional Ingredients Director.
  • "With this new patent, soft gel manufacturers in the U.S. can unlock the benefits of StabiCaps gelatin technology to produce high quality soft gel capsules with longer shelf stability and improved efficacy for customers."

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Retrieved on: 
Monday, November 27, 2023
European Patent Office, SAN, National Cancer Institute, Menopause, European Patent Convention, EPO, Ovarian cancer, Vaccine, Cancer, Partnership, Patent, Pharmaceutical industry, Cleveland Clinic

SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines."

Key Points: 
  • SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines."
  • Dr. Amit Kumar, Chairman and CEO of Anixa, stated, "Having recently been granted a U.S. patent for this novel ovarian cancer vaccine technology, we are delighted to receive the EPO's intention-to-grant notice, as a European patent would extend protection of the technology to additional potential markets."
  • The patent was invented by the late Dr. Vincent Tuohy, Dr. Suparna Mazumder, and Dr. Justin Johnson of Cleveland Clinic.
  • Anixa exclusively licensed the technology from Cleveland Clinic and is developing the technology in partnership with the not-for-profit, multispecialty academic medical center.

EQS-News: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform

Retrieved on: 
Thursday, December 14, 2023
European Patent Office, Safety, European Patent Convention, Spacecraft, HPHA, ATAC, Amanitin, EPO, Research, Patent, FSE, Gesellschaft mit beschränkter Haftung

Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).

Key Points: 
  • Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).
  • Site-specific ATAC conjugates comprise a genetically engineered antibody to which Heidelberg Pharma’s proprietary amatoxin payloads can be coupled via specific linkers.
  • The European patent also covers a method for the synthesis of such conjugates as well as their use in the treatment of diseases.
  • Professor Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma, comments: "We are very pleased that this patent has been granted, as it protects essential aspects of our ATAC technology, as e.g.

Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights

Retrieved on: 
Thursday, November 9, 2023
Excipient, Biotechnology, Regeneron Pharmaceuticals, European Journal of Pharmaceutical Sciences, Research, Journal, CMRA, Pharmacy, European Patent Office, Partnership, GMP, Safety, European Patent Convention, Caffeine, Pharmaceutical industry, Security (finance), Vaccine, Cryptocurrency

WOBURN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • “Comera continues to generate significant momentum, by expanding our patent portfolio, strengthening our cash position and advancing key partnerships.
  • The partnership includes a right to negotiate a license after the technical evaluation is complete.
  • Technical evaluation is expected to be completed in Q4 2023.
  • Comera had approximately $1.8 million in cash at September 30, 2023.

PlantArcBio Secures Patent from European Patent Office for Its Innovative DIP™ Platform Advancing Global Food Security

Retrieved on: 
Thursday, November 9, 2023
Patent, Intellectual property, EPO, Nature, European Patent Office, Plant, Gene, TASE, European Patent Convention, Soybean, IP, Climate change, Agriculture, Antibiotics

This novel platform is designed to discover genes for improving traits in crops and solidifies PlantArcBio's commitment to revolutionizing global food security by adapting crops to the challenges posed by climate change and enhancing sustainability.

Key Points: 
  • This novel platform is designed to discover genes for improving traits in crops and solidifies PlantArcBio's commitment to revolutionizing global food security by adapting crops to the challenges posed by climate change and enhancing sustainability.
  • we are delighted to receive this additional patent that recognizes the intrinsic benefits of our innovative technology."
  • This groundbreaking platform was developed by PlantArcBio to provide a game-changing method for adapting agricultural crops to adverse environmental and biological conditions.
  • In line with its core strategy, PlantArcBio remains committed to fortifying its competitive edge through robust Intellectual Property (IP) protection.